Using a new gene editing strategy, researchers from Yale University can correct mutations that cause thalassemia, a form of anemia. Their gene editing technique provided corrections to the mutations and alleviated the disease in mice, the researchers said. The finding could lead to studies of a similar gene therapy to treat people with inherited blood disorders.
Gene editing techniques have the potential to treat blood disorders that run in families, such as thalassemia and sickle cell anemia, but their application has been largely limited to cells in a laboratory and not living animals. To achieve gene editing in mice with thalassemia, professor of therapeutic radiology and of genetics Dr. Peter M. Glazer and his co-authors developed an alternative approach using a novel combination of nanoparticles, synthetic pieces of DNA, and a simple IV injection.
The cross-disciplinary research team identified a protein derived from bone marrow that has the ability to activate stem cells — the cells that are the most responsive to gene editing. They combined the protein with synthetic molecules, known as PNAs, that mimic DNA and bind to the target gene to form a triple helix. This triggers the cell’s own repair processes to fix the disease-causing mutation.
The team then utilized nanoparticles, developed in the lab of Mark Saltzman, professor of biomedical engineering, to transport the PNAs to the target mutation in mice. The final step was to use an IV injection to deliver the gene-editing package.
The researchers found that the technique corrected the mutation to such a degree that the mice no longer had symptoms of thalassemia. After 140 days, they tested hemoglobin levels in the animals and found them to be normal.
“The fundamental result here is that with nanoparticles containing PNAs, along with template DNA, and simple IV infusion of molecules, we achieved enough gene editing to effectively cure the anemia in mice that had thalassemia,” Glazer said.
In addition, because the research team used tiny pieces of DNA that were produced chemically, this technique avoided the type of unintended outcomes that other techniques, like CRISPR, can cause when they alter the genome. “We demonstrated we have extremely low off-target effects,” Glazer noted.
If the strategy proves effective in clinical studies, it could lead to the development of gene therapy for people with thalassemia, and potentially sickle cell disease and other inherited blood disorders, he said. “We might get enough cells corrected that individuals are not anemic anymore. We could achieve a symptomatic cure.”
Additional study authors include Raman Bahal, Nicole Ali McNeer, Elias Quijano, Yanfeng Liu, Parker Sulkowski, Audrey Turchick, Yi-Chien Lu, Dinesh C. Bhunia, Arunava Manna, Dale L. Greiner, Michael A. Brehm, Christopher J. Cheng, Francesc Lopez-Giraldez, Adele Ricciardi, Jagadish Beloor, Diane S. Krause, Priti Kumar, Patrick G. Gallagher, Demetrios T. Braddock, and Danith H. Ly. Saltzman, Glazer, Bahal, McNeer, and Ly are inventors on a related patent application.
This research was supported by the National Institutes of Health; by the National Science Foundation and DSF Charitable Foundation; and by the Robert E. Hunter Fund at Yale University.
Publication: Raman Bahal, et al., “In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery,” Nature Communications 7, Article number: 13304 (2016) doi:10.1038/ncomms13304
Source: Ziba Kashef, Yale University